-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Takeda announced that the U.
Non-small cell lung cancer is the most common type of lung cancer.
Mobocertinib is a potent oral small molecule tyrosine kinase inhibitor specifically designed to selectively target EGFR exon 20 insertion mutations.
The priority review qualification is awarded based on the results of Phase 1/2 clinical trials.
▲Phase 1/2 clinical trial results of Mobocertinib (picture source: reference [2])
Reference materials:
[1] Takeda Announces US FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer.
[w] Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy.